Qtrilmet - The New Drug for Treating Diabetes

21 August, 2020
Qtrilmet is newly proposed as a treatment for type 2 diabetes in adults who find it difficult to control it with traditional medications. The European Medicines Agency has established that its benefits outweigh the risks.

Qtrilmet is a medication used for treating diabetes and it contains three active substances: metformin, saxagliptin, and dapagliflozin. This drug is often prescribed as a treatment for patients with type 2 diabetes who can’t regulate their blood sugar levels with metformin alone or in combination with saxagliptin or dapagliflozin.

The use of Qtrilmet in diabetic patients also includes those who are taking sulfonylureas and can’t regulate blood glucose levels.

Uses of Qtrilmet

Qtrilmet is a prescription drug that comes in two different doses:

  • Metformin 850 mg/Saxagliptin 2.5 mg/Dapagliflozin 5 mg
  • Metformin 1000 mg/Saxagliptin 2.5 mg/Dapagliflozin 5 mg

When a doctor calculates the dose of Qtrilmet that you’ll need, they take into account the dose of metformin you’re taking until the moment you start treatment with the new drug. In general, once they assess the appropriate concentration for each case of Qtrilmet, the guideline to follow is 2 tablets, once a day, and taken with or after a meal.

The mechanism of action of Qtrilmet

Type 2 diabetes is a disease that’s due to insufficient production of insulin by the pancreas. Sometimes the body isn’t able to use insulin in an effective way, that is, it can’t transform glucose into energy.

Your glucose levels increase when you have diabetes. The good news is you can treat it with Qtrilmet. As we said above, this drug contains three active ingredients and each one of them serves a specific function:

  • Metformin. This ingredient decreases the production and absorption of glucose.
  • Saxagliptin. The function of this ingredient is to block the activity of hormones released after a meal so that the pancreas begins to produce insulin. When this blockage occurs, saxagliptin triggers the pancreas into producing more insulin when blood glucose levels rise. In addition, this active principle contributes to reducing the amount of glucose produced in the liver.
  • Dapagliflozin. This active substance locks a kidney protein called sodium-glucose cotransporter 2 (SGLT2). This protein keeps blood glucose from passing into the urine and being eliminated. When dapagliflozin works, it favors the passage of glucose into the urine so it can be eliminated, thus reducing the blood sugar levels.
The formula for Metformina.
The dose of metformin determines the use of Qtrilmet.

You may also be interested in How to Use Bay Leaves to Treat Diabetes

Benefits of Qtrilmet

The combination of metformin, saxagliptin, and dapagliflozin is useful because they’re effective in lowering blood sugar levels in patients with type II diabetes. The value here is the variation that occurs in the levels of glycosylated hemoglobin (HbA1c) after six months of treatment. This hemoglobin is a reliable indicator of blood sugar levels.

HbA1c values ​​in diabetic patients are usually above 8%. For this reason, the objective of the studies is to lower them to at least 7%. In general, Qtrilmet achieves a reduction of HbA1c levels by 0.51%.

However, in other studies, researchers observed that Qtrilmet reduced the mean HbA1c level by 0.82%, compared to patients who didn’t take this medication and in whom the observed a reduction of only 0.10%.

A blood test.
Glycated hemoglobin is a blood test to measure the effectiveness of diabetes treatments.

Side effects

Like all medications, Qtrilmet can lead to side effects. These are the most common:

  • Nose and throat infections
  • Hypoglycemia, when used in combination with a sulfonylurea

You shouldn’t take Qtrilmet if you’re hypersensitive to any of its three active ingredients. Also, people with kidney or liver problems shouldn’t use it.

Read also Eleven Complications of Diabetes

Conclusion

The European Medicines Agency determined that the benefits of Qtrilmet outweigh its risks so they recommend its use. However, they’re constantly monitoring the data they obtain in regard to its use.

 

  • (2019). Summary of opinion: Qtrilmet,metformin hydrochloride / saxagliptin / dapagliflozin. Case Medical Research. https://doi.org/10.31525/cmr-1d401a8

  • (2019). Human medicines European public assessment report (EPAR): Qtrilmet, metformin hydrochloride / saxagliptin / dapagliflozin, Diabetes Mellitus, Type 2, Date of authorisation: 11/11/2019, Status: Authorised. Case Medical Research. https://doi.org/10.31525/cmr-23ef88d

  • Reyes, B. (1982). Diabetes mellitus tipo II. Acta Méd. Colomb.